RxDoctor Payments Data

Cassandra Boduch

Psychiatry · Houston, TXNPI 1083177497

Payments from drug & device makers

$872in general payments, 2019–2025

Across 24 payments — averaging $36.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$285
  • Alkermes, Inc.$256
  • Supernus Pharmaceuticals, Inc.$162
  • Otsuka America Pharmaceutical, Inc.$53
  • Corium, LLC$36
  • Sunovion Pharmaceuticals Inc.$28
  • plus $53 from 3 others

What the payments were for

  • Food & beverage$872100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$872 in reported general payments places this provider in the 65th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$140,592
Medicare patients
228
Services billed
1,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole19$48,789
VyvanseLisdexamfetamine Dimesylate12$5,071
Aripiprazole17$1,244
Duloxetine Hcl41$719
Quetiapine Fumarate43$713
Bupropion XlBupropion Hcl30$625
Hydroxyzine Hcl22$514
Gabapentin36$510
Olanzapine32$445
Lamotrigine49$444
Venlafaxine Hcl ErVenlafaxine Hcl23$384
Oxcarbazepine14$332
Mirtazapine12$267
Bupropion Hcl SrBupropion Hcl24$258
Propranolol Hcl21$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$53$48,78919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →